Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

NCT02735629 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Opiate Induced Respiratory Depression

Interventions

DRUG: CX1739 - 300 mg
DRUG: CX1739 - 600 mg
DRUG: CX1739 - 900 mg
DRUG: Placebo

Sponsor

RespireRx

Collaborators

[object Object]